BioTek’s Gen5 Software Offers CVB Relative Potency Solution
Product News Aug 14, 2014
BioTek has announced the availability of customizable pre-programmed protocols for Gen5™ Data Analysis Software designed to estimate Relative Potency according to the requirements of the USDA APHIS Center for Veterinary Biologics (CVB) guidelines published March 14, 2014.
The CVBSOP0101.01 establishes the criteria that veterinary vaccine producers must use to estimate the relative potency of their test serials prior to submission for licensing through the CVB.
Several pre-programmed Gen5 protocols addressing both the full dose response and the linear methods for calculation are available for free download from BioTek’s website.
BioTek’s Gen5 capability provides CVB compliant laboratories with a convenient option to meet the stringent requirements of this SOP.
BioTek will be hosting a webinar on September 25, 2014 where they will describe the use of Gen5 software to estimate relative potency values per the CVB requirements.